Marinus Pharmaceuticals, Inc. - Common Stock (MRNS)
0.5380
0.00 (0.00%)
Marinus Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders
The company's lead product candidate aims to provide effective treatment options for conditions such as epilepsy. By leveraging their expertise in pharmacology and extensive research, Marinus Pharmaceuticals is dedicated to advancing therapeutic solutions that improve the quality of life for patients suffering from debilitating neurological conditions. Their commitment to innovation and patient care drives their research and development efforts in the field of neurology.
Marinus Pharmaceuticals stock plummeted after disappointing data from the Phase 3 TrustTSC trial of ganaxolone for seizures linked to tuberous sclerosis complex.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Marinus Pharmaceuticals' phase 3 RAISE trial on IV ganaxolone for refractory status epilepticus fails interim analysis. Future development to be assessed post final results review.
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also fell, dropping, 1.14% to 5,065.04.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P 500 also rose, gaining, 0.26% to 5,136.94.
